ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease-The Berlin Roadmap
File(s)PIIS2468024916300481.pdf (973.14 KB) Revised manuscript KI 090616.doc (506.5 KB)
Published version
Accepted version
Author(s)
Type
Journal Article
Abstract
To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases.
Date Issued
2016-07-27
Date Acceptance
2016-06-29
ISSN
2468-0249
Publisher
Elsevier
Start Page
327
End Page
339
Journal / Book Title
Kidney International Reports
Volume
1
Issue
4
Copyright Statement
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)
Sponsor
Arthritis Research UK
Grant Number
20108
Subjects
Science & Technology
Life Sciences & Biomedicine
Urology & Nephrology
autoimmunity
inflammation
lupus
rejection
stem cells
vasculitis
PROLIFERATIVE LUPUS NEPHRITIS
MESENCHYMAL STROMAL CELLS
DELAYS RENAL-FAILURE
DOMAIN-CONTAINING 7A
MEMBRANOUS NEPHROPATHY
ALPORT-SYNDROME
MYCOPHENOLATE-MOFETIL
MONOCLONAL-ANTIBODY
INDUCTION TREATMENT
NEPHROTIC SYNDROME
Publication Status
Published